A neoplasm that arises from SCHWANN CELLS of the cranial, peripheral, and autonomic nerves. Clinically, these tumors may present as a cranial neuropathy, abdominal or soft tissue mass, intracranial lesion, or with spinal cord compression. Histologically, these tumors are encapsulated, highly vascular, and composed of a homogenous pattern of biphasic fusiform-shaped cells that may have a palisaded appearance. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp964-5)
Adenocarcinoma of the common hepatic duct bifurcation. These tumors are generally small, sharply localized, and seldom metastasizing. G. Klatskin's original review of 13 cases was published in 1965. Once thought to be relatively uncommon, tumors of the bifurcation of the bile duct now appear to comprise more than one-half of all bile duct cancers. (From Holland et al., Cancer Medicine, 3d ed, p1457)
Neoplasms which arise from peripheral nerve tissue. This includes NEUROFIBROMAS; SCHWANNOMAS; GRANULAR CELL TUMORS; and malignant peripheral NERVE SHEATH NEOPLASMS. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1)
General disorders of the sclera or white of the eye. They may include anatomic, embryologic, degenerative, or pigmentation defects.
Infection in humans and animals caused by any fungus in the order Mucorales (e.g., Absidia, Mucor, Rhizopus etc.) There are many clinical types associated with infection of the central nervous system, lung, gastrointestinal tract, skin, orbit and paranasal sinuses. In humans, it usually occurs as an opportunistic infection in patients with a chronic debilitating disease, particularly uncontrolled diabetes, or who are receiving immunosuppressive agents. (From Dorland, 28th ed)
The surgical removal of the contents of the orbit. This includes the eyeball, blood vessels, muscles, fat, nerve supply, and periosteum. It should be differentiated from EYE EVISCERATION which removes the inner contents of the eye, leaving the sclera intact.
Removal of all of the organs and adjacent structures of the pelvis. It is usually performed to surgically remove cancer involving the bladder, uterine cervix, or rectum. (Stedman, 25th ed)
The removal of foreign material and devitalized or contaminated tissue from or adjacent to a traumatic or infected lesion until surrounding healthy tissue is exposed. (Dorland, 27th ed)
Diseases of the bony orbit and contents except the eyeball.
Diseases affecting or involving the PARANASAL SINUSES and generally manifesting as inflammation, abscesses, cysts, or tumors.
An order of zygomycetous fungi, usually saprophytic, causing damage to food in storage, but which may cause respiratory infection or MUCORMYCOSIS in persons suffering from other debilitating diseases.

Ethylnitrosourea-induced development of malignant schwannomas in the rat: two distinct loci on chromosome of 10 involved in tumor susceptibility and oncogenesis. (1/627)

Inbred rodent strains with differing sensitivity to experimental tumor induction provide model systems for the detection of genes that either are responsible for cancer predisposition or modify the process of carcinogenesis. Rats of the inbred BD strains differ in their susceptibility to the induction of neural tumors by N-ethyl-N-nitrosourea (EtNU). Newborn BDIX rats that are exposed to EtNU (80 microg/g body weight; injected s.c.) develop malignant schwannomas predominantly of the trigeminal nerves with an incidence >85%, whereas BDIV rats are entirely resistant. A T:A-->A:T transversion mutation at nucleotide 2012 of the neu (erbB-2) gene on chromosome 10, presumably the initial event in EtNU-induced schwannoma development, is later followed by loss of the wild-type neu allele. Genetic crosses between BDIX and BDIV rats served: (a) to investigate the inheritance of susceptibility; (b) to obtain animals informative for the mapping of losses of heterozygosity (LOH) in tumors with polymorphic simple sequence length polymorphisms (SSLPs); and (c) to localize genes associated with schwannoma susceptibility by linkage analysis with SSLPs. Schwannoma development was strongly suppressed in F1 animals (20% incidence). All of the F1 schwannomas displayed LOH on chromosome 10, with a consensus region on the telomeric tip encompassing D10Rat3, D10Mgh16 and D10Rat2 but excluding neu. A strong bias toward losing the BDIV alleles suggests the involvement of a BDIV-specific tumor suppressor gene(s). Targeted linkage analysis with chromosome 10 SSLPs in F2 intercross and backcross animals localized schwannoma susceptibility to a region around D10Wox23, 30 cM centromeric to the tip. Ninety-four % of F1 tumors exhibited additional LOH at this region. Two distinct loci on chromosome 10 may thus be connected with susceptibility to the induction and development of schwannomas in rats exposed to EtNU.  (+info)

Schwannoma with features mimicking neuroblastoma: report of two cases with immunohistochemical and ultrastructural findings. (2/627)

OBJECTIVE: A study of two cases of a rare variant of benign schwannoma showing areas mimicking neuroblastoma/peripheral primitive neuroectodermal tumour (PNET). METHODS: Sections of formalin fixed, paraffin embedded specimens were studied by tinctorial stains and immunohistochemistry, and the tissue retrieved from formalin was examined by electronmicroscopy in one case. RESULTS: The tumours were small and subcutaneous. Both showed features of benign schwannoma; one had a multinodular plexiform pattern. In addition, rosette-like structures consisting of collagenous cores surrounded by small round cells or slightly larger epithelioid cells were present. Tumour cells were positive for S100 protein, Leu7, and in one case GFAP, but were negative for neurofilament protein, synaptophysin, and MIC2. Type IV collagen surrounded individual cells. Electronmicroscopy in case 2 confirmed schwannian features (lamina, processes) and failed to show features of neuroblastoma (neuroendocrine granules). CONCLUSIONS: Benign schwannomas may contain rosette-like structures mimicking neuroblastoma/PNET. The techniques used confirmed schwannian differentiation only and eliminated neuroblastoma/PNET. These uncommon variants should be recognised by practising histopathologists to avoid erroneous diagnoses and inappropriate treatment.  (+info)

Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. (3/627)

Specific mutations in some tumor suppressor genes such as p53 can act in a dominant fashion. We tested whether this mechanism may also apply for the neurofibromatosis type-2 gene (NF2) which, when mutated, leads to schwannoma development. Transgenic mice were generated that express, in Schwann cells, mutant NF2 proteins prototypic of natural mutants observed in humans. Mice expressing a NF2 protein with an interstitial deletion in the amino-terminal domain showed high prevalence of Schwann cell-derived tumors and Schwann cell hyperplasia, whereas those expressing a carboxy-terminally truncated protein were normal. Our results indicate that a subset of mutant NF2 alleles observed in patients may encode products with dominant properties when overexpressed in specific cell lineages.  (+info)

Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma. (4/627)

BACKGROUND: Some 4%-5% of those who develop vestibular schwannomas have neurofibromatosis type 2 (NF2). Although about 10% of these patients present initially with a unilateral vestibular schwannoma, the risk for a patient with a truly sporadic vestibular schwannoma developing contralateral disease is unknown. METHODS: A United Kingdom survey of 296 patients with NF2 was reviewed for laterality of vestibular schwannoma at presentation and the presence of other NF2 related features. The time to presentation of bilateral disease was calculated for patients presenting with a unilateral tumour. Mutation analysis of the NF2 gene was carried out on all available cases presenting initially with unilateral disease. RESULTS: Of 240 patients with NF2 with vestibular schwannomas, 45 (18%; 32 sporadic, 13 familial) had either a unilateral tumour or delay in detection between the first and contralateral tumours. Among those tested for NF2 mutations, eight of 27 and nine of 13 were identified among sporadic and familial cases respectively. Sporadic cases showed a high female to male ratio and 19 of 32 have not as yet developed a contralateral tumour (mean 4.1 years after diagnosis of the first). Thirteen of 32 sporadic patients developed a contralateral tumour (mean 6.5 years after the first tumour diagnosis, range 0-22 years) compared with 11 of 13 familial patients (mean delay 5 years, range 0-16 years). Seven of the 45 patients had neither a family history of NF2 nor evidence of related tumours at initial presentation (six before the age of 35 years). CONCLUSION: The risk of patients with sporadic unilateral vestibular schwannomata developing a contralateral tumour in the absence of family history or other features of NF2 is low, but those presenting with other neurogenic tumours in addition to vestibular schwannoma are at high risk of harbouring an NF2 mutation in at least a proportion of their somatic cells.  (+info)

Midline cerebellar cystic schwannoma : a case report. (5/627)

An extremely unusual case of a cystic schwannoma in the region of the inferior vermis and posterior to the fourth ventricle in a fifteen year old boy is reported. The cystic tumour caused partial obstruction to the outflow of cerebrospinal fluid from fourth ventricle and resulted in development of supratentorial hydrocephalus. On investigations, the schwannoma simulated a Dandy-Walker cyst. The boy presented with symptoms of increased intracranial pressure. On surgery, the lesion was not arising from any cranial nerve, nor was it attached to brain parenchyma, blood vessel or to the dura. The possible histogenesis of the cystic schwannoma in a rare location is discussed.  (+info)

Association of lower cranial nerve schwannoma with spinal ependymoma in ? NF2. (6/627)

A 15 year old male, who had earlier been operated for intraspinal intramedullary ependymoma, subsequently developed a right cerebello pontine (CP) angle mass. A diagnosis of right CP angle ependymoma was considered, in view of established histology of previously operated spinal lesion. Histopathological examination of the well defined extra-axial mass, which was attached with ninth cranial nerve, however revealed a schwannoma. A diagnosis of Neurofibromatosis-2 (NF2) is strongly suspected, because of well established fact, that the spinal ependymomas may have association with lower cranial nerve schwannomas in NF2. Cranial and spinal MRI screening for early diagnosis of associated, asymptomatic lesions, in suspected cases of NF2, particularly in children, is recommended.  (+info)

Ventral T-1 neurinoma removed via hemilaminectomy without costotransversectomy--case report. (7/627)

A 39-year-old male presented with a spinal neurinoma originating from the T-1 anterior root and located ventral to the spinal cord. The tumor was removed by hemilaminectomy with only partial facetectomy without costotransversectomy. No stabilization was necessary, and no complications secondary to surgery occurred. Costotransversectomy is not necessary for neurinoma ventral to the spinal cord within the spinal canal at T-1 level because the transverse process protrudes more laterally and the spinal canal of the T-1 vertebra is wider than at other thoracic levels.  (+info)

Paediatric presentation of type 2 neurofibromatosis. (8/627)

BACKGROUND: Neurofibromatosis type 2 (NF2) is a highly penetrant autosomal dominant condition predisposing affected individuals to schwannomas and meningiomas. The proportion of children presenting with meningioma or schwannoma who have NF2 is not well described, and neither is the mode of presentation in most children with the inherited disease. AIMS: To determine the frequency of childhood meningioma and schwannoma cases caused by NF2 and the mode of presentation. METHODS: The records of the Manchester Children's Tumour Registry from 1954 were searched for cases of meningioma and schwannoma. Paediatric presentation in a large UK series of NF2 was also studied. RESULTS: 18% (61/334) of patients with NF2 on the UK database presented in the paediatric age group (0-15 years), frequently with the symptoms of an isolated tumour. More than half had no family history to alert the clinician to their susceptibility. Three of 22 children presenting with a meningioma on the Manchester Children's Tumour Registry have gone on to develop classic features of NF2. CONCLUSIONS: Clinicians should suspect NF2 in children presenting with meningioma, schwannoma, and skin features, such as neurofibromas/schwannomas, but fewer than 6 cafe au lait patches, who thus fall short of a diagnosis of neurofibromatosis type 1.  (+info)

A neurilemmoma, also known as schwannoma or peripheral nerve sheath tumor, is a benign, slow-growing tumor that arises from the Schwann cells, which produce the myelin sheath that surrounds and insulates peripheral nerves. These tumors can occur anywhere along the course of a peripheral nerve, but they most commonly affect the acoustic nerve (vestibulocochlear nerve), leading to a type of tumor called vestibular schwannoma or acoustic neuroma. Neurilemmomas are typically encapsulated and do not invade the surrounding tissue, although larger ones may cause pressure-related symptoms due to compression of nearby structures. Rarely, these tumors can undergo malignant transformation, leading to a condition called malignant peripheral nerve sheath tumor or neurofibrosarcoma.

A Klatskin's tumor, also known as a perihilar cholangiocarcinoma, is a rare and aggressive form of cancer that occurs at the junction where the right and left hepatic ducts come together to form the common hepatic duct, which then becomes the common bile duct. This type of tumor can obstruct the flow of bile from the liver into the small intestine, leading to jaundice, itching, abdominal pain, and other symptoms. Klatskin's tumors are often difficult to diagnose and treat due to their location and tendency to spread quickly. Surgical resection is the preferred treatment option when possible, although chemotherapy and radiation therapy may also be used in some cases.

Peripheral nervous system (PNS) neoplasms refer to tumors that originate in the peripheral nerves, which are the nerves outside the brain and spinal cord. These tumors can be benign or malignant (cancerous). Benign tumors, such as schwannomas and neurofibromas, grow slowly and do not spread to other parts of the body. Malignant tumors, such as malignant peripheral nerve sheath tumors (MPNSTs), can invade nearby tissues and may metastasize (spread) to other organs.

PNS neoplasms can cause various symptoms depending on their location and size. Common symptoms include pain, weakness, numbness, or tingling in the affected area. In some cases, PNS neoplasms may not cause any symptoms until they become quite large. Treatment options for PNS neoplasms depend on several factors, including the type, size, and location of the tumor, as well as the patient's overall health. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Scleral diseases refer to conditions that affect the sclera, which is the tough, white outer coating of the eye. The sclera helps to maintain the shape of the eye and provides protection for the internal structures. Scleral diseases can cause inflammation, degeneration, or thinning of the sclera, leading to potential vision loss or other complications. Some examples of scleral diseases include:

1. Scleritis: an inflammatory condition that causes pain, redness, and sensitivity in the affected area of the sclera. It can be associated with autoimmune disorders, infections, or trauma.
2. Episcleritis: a less severe form of inflammation that affects only the episclera, a thin layer of tissue overlying the sclera. Symptoms include redness and mild discomfort but typically no pain.
3. Pinguecula: a yellowish, raised deposit of protein and fat that forms on the conjunctiva, the clear membrane covering the sclera. While not a disease itself, a pinguecula can cause irritation or discomfort and may progress to a more severe condition called a pterygium.
4. Pterygium: a fleshy growth that extends from the conjunctiva onto the cornea, potentially obstructing vision. It is often associated with prolonged sun exposure and can be removed surgically if it becomes problematic.
5. Scleral thinning or melting: a rare but serious condition where the sclera degenerates or liquefies, leading to potential perforation of the eye. This can occur due to autoimmune disorders, infections, or as a complication of certain surgical procedures.
6. Ocular histoplasmosis syndrome (OHS): a condition caused by the Histoplasma capsulatum fungus, which can lead to scarring and vision loss if it involves the macula, the central part of the retina responsible for sharp, detailed vision.

It is essential to consult an ophthalmologist or eye care professional if you experience any symptoms related to scleral diseases to receive proper diagnosis and treatment.

Mucormycosis is a serious and often life-threatening invasive fungal infection caused by the Mucorales family of fungi. It primarily affects people with weakened immune systems, such as those with uncontrolled diabetes, cancer, organ transplant recipients, or those who have been treated with high doses of corticosteroids.

The infection typically begins in the respiratory tract after inhaling spores from the environment, but it can also occur through skin wounds or gastrointestinal exposure to the fungi. The infection can quickly spread to other parts of the body, including the sinuses, brain, and lungs, causing tissue damage and necrosis.

Symptoms of mucormycosis depend on the site of infection but may include fever, cough, shortness of breath, chest pain, headache, sinus congestion, facial swelling, and blackened areas of skin or tissue. Treatment typically involves a combination of antifungal medications, surgical debridement of infected tissue, and management of underlying medical conditions that increase the risk of infection.

Orbital evisceration is not a medical condition itself, but rather a surgical procedure. In ophthalmology (the branch of medicine dealing with the eye), orbital evisceration refers to the removal of the contents of the eye, leaving the scleral shell, extraocular muscles, and orbital fat intact. This is often performed for therapeutic or cosmetic reasons, such as in cases of painful blind eyes or severely disfigured eyes. The empty eye socket is then often fitted with a prosthetic eye to restore a more natural appearance.

Pelvic exenteration is a major surgical procedure that involves the removal of all or most of the organs within the pelvic cavity. This procedure is typically performed as a last resort to treat recurrent or advanced pelvic cancers, such as rectal, colon, bladder, cervical, endometrial, or vulvar cancer, that have not responded to other treatments like chemotherapy or radiation therapy.

During the surgery, the surgeon removes the reproductive organs (ovaries, fallopian tubes, uterus, and vagina), bladder, rectum, and sometimes parts of the colon. In some cases, nearby lymph nodes and other tissues may also be removed. After removing these organs, the surgeon creates new pathways for urine and stool to leave the body.

Pelvic exenteration is a complex and extensive surgery that carries significant risks, including bleeding, infection, damage to nearby nerves or blood vessels, and complications related to the creation of new pathways for waste elimination. However, it can be an effective treatment option for some patients with advanced pelvic cancers who have exhausted other treatment options.

Debridement is a medical procedure that involves the removal of dead, damaged, or infected tissue to improve the healing process or prevent further infection. This can be done through various methods such as surgical debridement (removal of tissue using scalpel or scissors), mechanical debridement (use of wound irrigation or high-pressure water jet), autolytic debridement (using the body's own enzymes to break down and reabsorb dead tissue), and enzymatic debridement (application of topical enzymes to dissolve necrotic tissue). The goal of debridement is to promote healthy tissue growth, reduce the risk of infection, and improve overall wound healing.

Orbital diseases refer to a group of medical conditions that affect the orbit, which is the bony cavity in the skull that contains the eye, muscles, nerves, fat, and blood vessels. These diseases can cause various symptoms such as eyelid swelling, protrusion or displacement of the eyeball, double vision, pain, and limited extraocular muscle movement.

Orbital diseases can be broadly classified into inflammatory, infectious, neoplastic (benign or malignant), vascular, traumatic, and congenital categories. Some examples of orbital diseases include:

* Orbital cellulitis: a bacterial or fungal infection that causes swelling and inflammation in the orbit
* Graves' disease: an autoimmune disorder that affects the thyroid gland and can cause protrusion of the eyeballs (exophthalmos)
* Orbital tumors: benign or malignant growths that develop in the orbit, such as optic nerve gliomas, lacrimal gland tumors, and lymphomas
* Carotid-cavernous fistulas: abnormal connections between the carotid artery and cavernous sinus, leading to pulsatile proptosis and other symptoms
* Orbital fractures: breaks in the bones surrounding the orbit, often caused by trauma
* Congenital anomalies: structural abnormalities present at birth, such as craniofacial syndromes or dermoid cysts.

Proper diagnosis and management of orbital diseases require a multidisciplinary approach involving ophthalmologists, neurologists, radiologists, and other specialists.

Paranasal sinus diseases refer to a group of medical conditions that affect the paranasal sinuses, which are air-filled cavities located within the skull near the nasal cavity. These sinuses include the maxillary, frontal, ethmoid, and sphenoid sinuses.

Paranasal sinus diseases can be caused by a variety of factors, including viral, bacterial, or fungal infections, allergies, structural abnormalities, or autoimmune disorders. Some common paranasal sinus diseases include:

1. Sinusitis: Inflammation or infection of the sinuses, which can cause symptoms such as nasal congestion, thick nasal discharge, facial pain or pressure, and reduced sense of smell.
2. Nasal polyps: Soft, benign growths that develop in the lining of the nasal passages or sinuses, which can obstruct airflow and cause difficulty breathing through the nose.
3. Sinonasal tumors: Abnormal growths that can be benign or malignant, which can cause symptoms such as nasal congestion, facial pain, and bleeding from the nose.
4. Sinus cysts: Fluid-filled sacs that form in the sinuses, which can cause symptoms similar to those of sinusitis.
5. Fungal sinusitis: Infection of the sinuses with fungi, which can cause symptoms such as nasal congestion, facial pain, and thick, discolored mucus.

Treatment for paranasal sinus diseases depends on the underlying cause and severity of the condition. Treatment options may include medications, such as antibiotics, antihistamines, or corticosteroids, as well as surgical intervention in more severe cases.

Mucorales is a order of fungi that includes several genera of mold-like fungi, such as Mucor, Rhizopus, and Absidia. These fungi are commonly found in soil, decaying vegetation, and animal manure. Some species can cause mucormycosis, a serious and often life-threatening invasive fungal infection that primarily affects people with weakened immune systems, such as those with uncontrolled diabetes, cancer, or organ transplants. The infection typically begins in the respiratory tract, but it can spread to other parts of the body, including the sinuses, brain, and lungs. Mucormycosis is difficult to diagnose and treat, and it has a high mortality rate.

Previous designations for schwannomas include neurinoma and neurilemmoma. The candidate schwannomatosis gene, named SMARCB1, is ...
2002). "Pneumosinus dilatans Associated with Orbital Neurilemmoma" (PDF). Chinese Medical Journal. Archived from the original ( ...
A schwannoma (or neurilemmoma) is a usually benign nerve sheath tumor composed of Schwann cells, which normally produce the ...
... neurilemmoma and neurofibroma which are large growing painless tumours usually found on the tongue (3). Neurofibroma may occur ...
... neurilemmoma, neurinoma, neurolemmoma, Schwann cell tumor) Solitary angiokeratoma Solitary cutaneous leiomyoma Solitary ...
... neurilemmoma MeSH C04.557.580.625.650.595.610 - neuroma, acoustic MeSH C04.557.580.625.650.700 - paraganglioma MeSH C04.557. ... neurilemmoma MeSH C04.557.465.625.650.595.610 - neuroma, acoustic MeSH C04.557.465.625.650.595.610.500 - neurofibromatosis 2 ... neurilemmoma MeSH C04.557.580.600.610.595.610 - neuroma, acoustic MeSH C04.557.580.600.610.595.610.500 - neurofibromatosis 2 ... neurilemmoma MeSH C04.557.580.600.580 - neurofibroma MeSH C04.557.580.600.580.585 - neurofibroma, plexiform MeSH C04.557. ...
... neurilemmoma MeSH C10.551.775.500.750 - neurofibroma MeSH C10.551.775.500.750.500 - neurofibroma, plexiform MeSH C10.551. ... neurilemmoma MeSH C10.668.829.725.500.600 - neurofibroma MeSH C10.668.829.725.500.600.500 - neurofibroma, plexiform MeSH ...
... neurilemmoma, endometrioma, glomus tumor and granular cell tumor; the mnemonic "BLEND-AN-EGG" may be helpful). Other skin ...
encoded search term (Neurilemmoma (Schwannoma)) and Neurilemmoma (Schwannoma) What to Read Next on Medscape ... Neurilemmoma (Schwannoma). Updated: Oct 31, 2022 * Author: Ian D Dickey, MD, FRCSC, LMCC; Chief Editor: Harris Gellman, MD more ... 2] Neurilemmoma can be associated with von Recklinghausen disease; when this is the case, multiple tumors often are present. ... Neurilemmoma is the most common neurogenic tumor, but precise prevalence figures are not available. These tumors affect persons ...
Home / Keyword neurilemmoma [8]. View: Monthly list ✔ Monthly list ✔ Monthly calendar ✔ Weekly list ...
A neurilemmoma is a benign, usually encapsulated neoplasm derived from Schwann cells and, along with neurofibroma, constitutes ... encoded search term (Dermatologic Manifestations of Neurilemmoma (Schwannoma)) and Dermatologic Manifestations of Neurilemmoma ... Dermatologic Manifestations of Neurilemmoma (Schwannoma). Updated: Jan 21, 2015 * Author: Kara Melissa T Torres, MD, DPDS; ... In melanotic neurilemmoma, the age range was reported at 10-84 years, with a mean age of 37 years. Overall, approximately 75% ...
When the neurilemmoma appears in the oral cavity, this lesion is most frequently found in the tongue5, particularly in ... Neurilemmoma or Schwanoma is a rare, benign, neurogenic, encapsulated and slow growing tumor. It originates from Schwann cells ... Although the neurilemmoma does not present specific clinical characteristics, and is similar to other lesions such as fibroma ... In this article, a rare case of neurilemmoma located in the jugal mucosa of a child only 9 years old is reported. ...
Scope Note: Notes = A neoplasm that arises from SCHWANN CELLS of the cranial, peripheral, and autonomic nerves. Clinically, these tumors may present as a cranial neuropathy, abdominal or soft tissue mass, intracranial lesion, or with spinal cord compression. Histologically, these tumors are encapsulated, highly vascular, and composed of a homogenous pattern of biphasic fusiform-shaped cells that may have a palisaded appearance.,Created For = LHSA-Dott,Use For = Neurinoma ...
Conditions mentioned include: spinal neurilemmoma; neuroma cauda equina; and crural pain. Surgical and nonsurgical treatment ...
also-called,Acoustic neurilemmoma,/also-called, ,also-called,Acoustic neurinoma,/also-called, ...
Neurilemmoma / genetics * Oligodendroglioma / chemistry * Reference Values Substances * ATP Binding Cassette Transporter, ...
Neurilemmoma / diagnosis * Neurilemmoma / surgery* * Pelvis / diagnostic imaging* * Sacrum / diagnostic imaging * Sacrum / ...
Ganglia; lipoma; neurilemmoma. *Inflammatory synovitis. *Pigmented villonodular synovitis. *Tarsal coalition. *Accessory ...
Previous designations for schwannomas include neurinoma and neurilemmoma. The candidate schwannomatosis gene, named SMARCB1, is ...
Neurilemmoma. Neuroblastoma. Neurocytoma. Neurofibrosarcoma. Olfactory Neuroblastoma (Esthesioneuroblastoma). Osteogenic ...
Dahl I: Ancient neurilemmoma (schwannoma). Acta Pathol Microbiol (A) 1977;85: 812-818. ...
An acoustic neuroma is also known as a schwannoma, vestibular schwannoma, or neurilemmoma. ...
Neurilemmoma of the ciliary body: report of a case. (1 September, 1983) Free R Rosso, R Colombo, G Ricevuti ...
Neurilemmoma of the orbit - a case report. p. 45. P Ramchander, OM Satyendran. ...
OBJECTIVE: This study will demonstrate an individualized approach to hearing preservation and tumor management in pediatric patients with neurofibromatosis type 2 (NF2). The unique nature of each case discussed will provide valuable guiding principles for the treating surgeon. PATIENTS: Pediatric patients under the care of the senior authors presenting with bilateral vestibular schwannoma and NF2. INTERVENTIONS: Interventions used for hearing optimization, in conjunction with surgical interventions, include use of hearing aids, cochlear implants, auditory brainstem implants, radiation therapy, and chemotherapeutic agents such as bevacizumab. RESULTS: Pediatric patients with NF2 present a unique and difficult challenge to the neurotologist. These children are still developing physically, mentally, and socially. They generally have a poorer prognosis and diminished life expectancy. Considerations of utmost importance include management of the tumor with the goal of minimizing outcomes such as ...
Mediastinal vagal neurilemmoma]] *[[Non-hodgkins lymphoma]] *[[Normal aorta associated with right lung agenesis]] *[[Plombage ... Mediastinal vagal neurilemmoma]], [[Non-hodgkins lymphoma]], [[Pseudolymphoma]], [[Right lung cancer]], [[Thoracic ... Mediastinal vagal neurilemmoma]], [[Thoracic neuroblastoma]] ,- ,-bgcolor="LightSteelBlue" , Nutritional / Metabolic , ...
Paraffin sections show a partially cystic moderately hypercellular neurilemmoma (Schwannoma). This is composed of both Antoni-A ...
Neurilemmoma Mimicking a Multilocular Cystic Lesion of the Liver. Akihiro Yoshida, Kentaro Yamao, Mamoru Takenaka, Atsushi ... We herein report an 80-year-old man with a multilocular cystic neurilemmoma mimicking a liver lesion. Preoperative images ... The final diagnosis was a neurilemmoma. Porta hepatic neurilemmomas are rare. When we encounter a multilocular cystic lesion of ...
NEURILEMMOMA, MULTIPLE, SPINAL CORD; VON RECKLINGHAUSENS DISEASE - 00201842.jpg ... GROSS: NERVOUS: SPINAL CORD: NEURILEMMOMA, MULTIPLE, SPINAL CORD; VON RECKLINGHAUSENS DISEASE. Author. Peter Anderson. ...
Schwannoma or neurilemmoma (NL) is a well-defined, usually benign, tumour arising from the nerve sheath (Schwann cell). It may ...
Schawnnoma or neurilemmoma is a benign slow-growing neoplasm of Schwann cells that can arise from any cranial, peripheral or ... Schawnnoma or neurilemmoma is a benign slow-growing neoplasm of Schwann cells that can arise from any cranial, peripheral or ...
RESULTS: In the first patient with a tumor in projection on the isthmus and the left thyroid lobe, neurilemmoma was discovered ... Neurilemmoma:diagnosis, Thyroid Gland:pathology, Thyroid Neoplasms:diagnosis,. OBJECTIVE: Neck nodular lesions may derive from ...
Neurilemmoma (Schwannoma) of the thyroid gland: A rare case presentation. Nidhi Mangal, Anil K Agarwal, Veena K Sharma, ...
Central neurilemmoma of maxilla. A case report Villanueva Maffei, Julio; Gigoux, Carlos; Solé, Fernando (1995) Central ... A case of central neurilemmoma of the maxilla in a 14-year-old girl, the surgical treatment, and results ... ...
BACKGROUND: Data on radiotherapy for trigeminal schwannomas (TSs) and comparison of stereotactic radiosurgery (SRS) with fractionated stereotactic radiotherapy (FSRT) are limited. OBJECTIVE: We present a large retrospective review of our institutional experience treating TSs with SRS and FSRT. We also describe a flare phenomenon experienced by some patients. METHODS: The records of 23 consecutive TSs patients treated with radiotherapy between 1996 and 2011 were reviewed. We investigated radiographic response, tumor control, and toxicity. RESULTS: Ten patients underwent SRS and 13 underwent FSRT, with median clinical follow-up of 32 months (range, 3-120 months). Tumor control at 5 and 10 years was 94% overall. Symptom control at 5 years was achieved in 48% of all patients, with nonsignificant improvement in more patients in the FSRT group than those in the SRS group (56% vs 40%, P = .37). Acute toxicity was higher in the FSRT group (38.5 vs 0%, P , .01), although lesions treated with FSRT were ...
Neurilemmoma; Acoustic Schwannoma; Acoustic Neuroma). Definition. A vestibular schwannoma is a tumor that grows on a nerve that ...
Neurilemmoma or benign schwannoma of the palate]. / Neurilemmoma o shwannona benigno de paladar. Beato, A. ... Neurilemmoma o shwannona benigno de paladar / [Neurilemmoma or benign schwannoma of the palate] Beato, A. ... Neurilemmoma o shwannona benigno de paladar. / [Neurilemmoma or benign schwannoma of the palate] Beato, A. ...
Powered by Pure, Scopus & Elsevier Fingerprint Engine™ © 2023 Elsevier B.V We use cookies to help provide and enhance our service and tailor content. By continuing you agree to the use of cookies. Log in to Pure. ...

No FAQ available that match "neurilemmoma"

No images available that match "neurilemmoma"